PPARγ Mechanism of Action Studies

  • Steven Kliewer
Part of the Medical Science Symposia Series book series (MSSS, volume 18)

Abstract

Adult onset (Type 2) diabetes mellitus afflicts more than 100 million people worldwide, and its prevalence is soaring in developed countries with high fat diets and increasingly sedentary lifestyles. The development of insulin resistance is an early step in the onset of Type 2 diabetes. The glitazones, including rosiglitazone and pioglitazone, and tyrosine analogs GI262570 and GW1929 are promising new drugs for the treatment of Type 2 diabetes [1]. These drugs improve insulin sensitivity and reduce glucose levels in Type 2 diabetics by increasing glucose utilization in muscle and decreasing glucose production in the liver [2]. These drugs have the added therapeutic benefits of increasing high density lipoprotein cholesterol levels and decreasing triglyceride and free fatty acid (FFA) levels.

Keywords

Cholesterol Carbohydrate Tyrosine Citrate Lipase 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: From orphan receptors to drug discovery. J Med Chem 2000;43:527–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661–69.PubMedCrossRefGoogle Scholar
  3. 3.
    Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Brown KK, Henke BR, Blanchard SG, et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999;48:1415–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Way JM, Harrington WW, Brown KK, et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001;142:1269–77.PubMedCrossRefGoogle Scholar
  6. 6.
    Shimkets RA, Lowe DG, Tai JT, et al. Gene expression analysis by transcript profiling coupled to a gene database query. Nature Biotechnol 1999;17:798–803.CrossRefGoogle Scholar
  7. 7.
    Flier JS, Hollenberg AN. ADD-1 provides major new insight into the mechanism of insulin action. Proc Natl Acad Sci USA 1999;96:14191–92.PubMedCrossRefGoogle Scholar
  8. 8.
    Sreenan S, Keck S, Fuller T, Cockburn B, Burant CF. Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. Am J Physiol 1999;276:E1119–29.PubMedGoogle Scholar
  9. 9.
    Randle PJ. Regulatory interactions between lipids and carbohydrates: The glucose fatty acid cycle after 35 years. Diabetes Metab Rev 1998;14(4):263–83.PubMedCrossRefGoogle Scholar
  10. 10.
    Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000; 11:351–56.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2002

Authors and Affiliations

  • Steven Kliewer

There are no affiliations available

Personalised recommendations